Daniel Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel Taylor has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa Kipke
Division of Hematology and Oncology, Department of Internal Medicine, Ascension Genesys Hospital, Grand Blanc, MI 48439, USA
1 shared publication - Brandon Wiggins
Internal Medicine, Ascension Genesys Hospital, Grand Blanc, USA
1 shared publication - Daniel Ramirez
Division of Gastroenterology, Department of Internal Medicine, Ascension Genesys Hospital, Grand Blanc, MI 48439, USA
1 shared publication - Mark Minaudo
Gastroenterology and Hepatology, Ascension Health, Grand Blanc, USA
1 shared publication - William Reichardt
Division of Hematology and Oncology, Department of Internal Medicine, Ascension Genesys Hospital, Grand Blanc, MI 48439, USA
1 shared publication
Latest Publications
- Open Access
- 21 September 2022
- Published by MDPI AG in Hematology Reports
- Vol. 14 (4) , 290-293
Medication-Induced Factor V Inhibition in the Setting of Refractory Coagulopathy
Liver cirrhosis is commonly associated with coagulopathies, typically demonstrated by elevated prothrombin time, international normalized ratio, and partial thromboplastin time. In the setting of bleeding related to coagulopathies, oftentimes physicians try to reverse coagulopathy through a variety of methods including the use of vitamin K and fresh frozen plasma. Rarely, attempts at reversing coagulopathy are unsuccessful due to severe disease or factor inhibitors. The treatment of acquired factor V inhibitors is primarily performed through immunosuppression and supportive care for the initial bleeding episode. Early detection and treatment of factor V inhibition is challenging in a setting of underlying cirrhosis-related coagulopathy.
- 21 September 2022
- Published by MDPI AG in Hematology Reports
- Vol. 14 (4) , 290-293
Open AccessMedication-Induced Factor V Inhibition in the Setting of Refractory Coagulopathy
Liver cirrhosis is commonly associated with coagulopathies, typically demonstrated by elevated prothrombin time, international normalized ratio, and partial thromboplastin time. In the setting of bleeding related to coagulopathies, oftentimes physicians try to reverse coagulopathy through a variety of methods including the use of vitamin K and fresh frozen plasma. Rarely, attempts at reversing coagulopathy are unsuccessful due to severe disease or factor inhibitors. The treatment of acquired factor V inhibitors is primarily performed through immunosuppression and supportive care for the initial bleeding episode. Early detection and treatment of factor V inhibition is challenging in a setting of underlying cirrhosis-related coagulopathy.